SBFM
Income statement / Annual
Last year (2024), Sunshine Biopharma, Inc.'s total revenue was $34.87 M,
an increase of 44.75% from the previous year.
In 2024, Sunshine Biopharma, Inc.'s net income was -$5.13 M.
See Sunshine Biopharma, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$34.87 M |
$24.09 M |
$4.35 M |
$228.43 K |
$71.41 K |
$21.12 K |
$447.20 K |
$0.00 |
$0.00 |
$1.71 K |
| Cost of Revenue |
$24.20 M
|
$15.75 M
|
$2.65 M
|
$117.83 K
|
$25.85 K
|
$11.05 K
|
$391.08 K
|
$6.63 K
|
$60.73 K
|
$384.58 K
|
| Gross Profit |
$10.67 M
|
$8.34 M
|
$1.70 M
|
$110.60 K
|
$45.56 K
|
$10.07 K
|
$56.12 K
|
-$6.63 K
|
-$60.73 K
|
-$383.00 K
|
| Gross Profit Ratio |
0.31
|
0.35
|
0.39
|
0.48
|
0.64
|
0.48
|
0.13
|
0
|
0
|
-224.24
|
| Research and Development Expenses |
$933.90 K
|
$1.86 M
|
$811.86 K
|
$672.21 K
|
$60.95 K
|
$15.20 K
|
$12.80 K
|
$0.00
|
$32.79 K
|
$8.66 K
|
| General & Administrative Expenses |
$14.00 M
|
$10.10 M
|
$8.90 M
|
$1.87 M
|
$547.42 K
|
$622.73 K
|
$381.91 K
|
$850.56 K
|
$899.58 K
|
$769.08 K
|
| Selling & Marketing Expenses |
$940.28 K
|
$734.25 K
|
$578.09 K
|
$0.00
|
$0.00
|
$0.00
|
$755.22 K
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$14.94 M
|
$10.83 M
|
$9.48 M
|
$1.87 M
|
$547.42 K
|
$622.73 K
|
$1.14 M
|
$850.56 K
|
$899.58 K
|
$769.08 K
|
| Other Expenses |
$610.62 K
|
$438.88 K
|
$80.40 K
|
$12.74 K
|
$14.07 K
|
$13.77 K
|
$14.36 K
|
$6.63 K
|
$60.73 K
|
$4.25 K
|
| Operating Expenses |
$16.48 M
|
$13.12 M
|
$10.37 M
|
$2.55 M
|
$622.44 K
|
$651.71 K
|
$1.22 M
|
$857.19 K
|
$993.11 K
|
$397.40 K
|
| Cost And Expenses |
$40.69 M
|
$28.88 M
|
$13.02 M
|
$2.67 M
|
$648.28 K
|
$662.76 K
|
$1.61 M
|
$857.19 K
|
$993.11 K
|
$781.99 K
|
| Interest Income |
$496.00 K
|
$811.97 K
|
$518.65 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$8.77 K
|
$137.31 K
|
$39.41 K
|
$328.82 K
|
$168.11 K
|
$115.90 K
|
$159.42 K
|
$104.83 K
|
$34.73 K
|
$307.21 K
|
| Depreciation & Amortization |
$223.53 K
|
$149.15 K
|
$25.16 K
|
$12.74 K
|
$14.07 K
|
$13.77 K
|
$49.36 K
|
$6.63 K
|
$60.73 K
|
$4.25 K
|
| EBITDA |
-$5.15 M |
-$3.82 M |
-$26.45 M |
-$12.10 M |
-$2.60 M |
-$948.38 K |
-$1.95 M |
-$928.78 K |
-$932.38 K |
-$1.34 M |
| EBITDA Ratio |
-0.15
|
-0.16
|
-6.09
|
-52.95
|
-36.44
|
-44.9
|
-4.35
|
0
|
0
|
-785.13
|
| Operating Income Ratio |
-0.17
|
-0.2
|
-6.21
|
-10.68
|
-8.08
|
-30.38
|
-2.61
|
0
|
0
|
-456.67
|
| Total Other Income/Expenses Net |
$443.15 K
|
$674.42 K
|
$489.61 K
|
-$10.00 M
|
-$2.21 M
|
-$436.42 K
|
-$990.00 K
|
-$183.05 K
|
-$2.50 M
|
-$873.00 K
|
| Income Before Tax |
-$5.37 M
|
-$4.11 M
|
-$26.51 M
|
-$12.44 M
|
-$2.78 M
|
-$1.08 M
|
-$2.16 M
|
-$1.04 M
|
-$3.50 M
|
-$1.65 M
|
| Income Before Tax Ratio |
-0.15
|
-0.17
|
-6.1
|
-54.44
|
-38.99
|
-51.04
|
-4.82
|
0
|
0
|
-967.8
|
| Income Tax Expense |
-$235.00 K
|
$395.17 K
|
$233.30 K
|
$0.00
|
$0.00
|
$0.00
|
-$41.53 K
|
$1.29 K
|
$0.00
|
$0.00
|
| Net Income |
-$5.13 M
|
-$4.51 M
|
-$26.74 M
|
-$12.44 M
|
-$2.78 M
|
-$1.66 M
|
-$2.16 M
|
-$1.04 M
|
-$3.50 M
|
-$1.65 M
|
| Net Income Ratio |
-0.15
|
-0.19
|
-6.15
|
-54.44
|
-38.99
|
-78.61
|
-4.82
|
0
|
0
|
-967.8
|
| EPS |
-7.32 |
-351.36 |
-3523.64 |
-9774.32 |
-3214.89 |
-18866.94 |
-142 |
-23.84 |
-164.63 |
-1652908 |
| EPS Diluted |
-7.32 |
-351.36 |
-3523.64 |
-9520 |
-3214.89 |
-18866.94 |
-142 |
-23.84 |
-164.63 |
-1652908 |
| Weighted Average Shares Out |
$701.75 K
|
$12.17 K
|
$7.59 K
|
$1.31 K
|
$866.00
|
$1.77 K
|
$15.23 K
|
$43.63 K
|
$2.66
|
$1.53 K
|
| Weighted Average Shares Out Diluted |
$701.75 K
|
$12.17 K
|
$7.59 K
|
$1.31 K
|
$866.00
|
$1.77 K
|
$15.23 K
|
$43.63 K
|
$2.66
|
$1.53 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
